Message #26 From:
NewsBot Date: March 12, 2007 10:57:00 AM
EGEI News eGene Receives Notification That the European Patent Office Has Allowed Its Patent Application ''OPTICAL DETECTION IN A MULTI-CHANNEL BIO-SEPARATION SYSTEM''
IRVINE, Calif.--(BUSINESS WIRE)--eGene Inc. (OTCBB:EGEI), a leading biotechnology company and developer of a compact and automated digital genetic analyzer, announced today that the Company has received notification that the European Patent Office has allowed its patent application “OPTICAL DETECTION IN A MULTI-CHANNEL BIO-SEPARATION SYSTEM.” This marks the Company's 11th patent worldwide.
Mr. Varouj Amirkhanian, Executive V.P. & R&D Director, said, “We continue to strengthen our patent portfolio with the addition of this European patent. We believe our revolutionized technology of the low-cost and high-performance digital analyzer system has great market potential for biological material testing applications. We are going to develop products that can detect, quantify, identify and characterize biomolecules, which include DNA, RNA, carbohydrates and proteins in the life science market.”
About eGene Inc.
eGene Inc. (www.egeneinc.com) focuses its core technologies of capillary electrophoresis, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. eGene developed the HDA-GT12(TM) (high-performance DNA analyzer for genotyping on 12 channels). The system analyzes the genetic fingerprints of living organisms. It performs fast DNA sample screening, genotyping analysis, gene expression to replace the current slab gel electrophoresis tools. The Company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to publicly release any revision, which may be made to reflect events or circumstances after the date hereof.
